Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MTVA MetaVia	$0.73 -2.4%	$0.83	$0.63 ▼ $5.30	$14.32M	0.18	406,276 shs	651,867 shs
MYNZ Mainz Biomed	$1.83 -8.0%	$2.62	$1.80 ▼ $26.56	$6.30M	0.31	131,769 shs	115,689 shs
NLSP NLS Pharmaceutics	$2.28 -4.6%	$1.77	$1.30 ▼ $18.39	$8.20M	0.05	888,769 shs	150,210 shs
SXTC China SXT Pharmaceuticals	$1.83 -10.3%	$1.87	$0.95 ▼ $11.92	$28.97M	1.11	1.19 million shs	53,894 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MTVA MetaVia	-2.39%	+5.76%	+9.76%	-50.53%	+73,209,900.00%
MYNZ Mainz Biomed	-8.04%	-11.81%	-19.38%	-58.03%	-93.11%
NLSP NLS Pharmaceutics	-4.60%	-0.87%	+38.18%	+44.30%	+1,731.33%
SXTC China SXT Pharmaceuticals	-10.29%	-12.44%	+9.58%	-35.11%	-79.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MTVA MetaVia	2.4228 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.0	1.3
MYNZ Mainz Biomed	2.7678 of 5 stars	3.3	5.0	0.0	0.0	1.3	0.8	1.3
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.3788 of 5 stars	0.0	3.0	0.0	0.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MTVA MetaVia	3.00	Buy	$7.50	924.45% Upside
MYNZ Mainz Biomed	2.50	Moderate Buy	$14.00	665.03% Upside
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, MTVA, NLSP, and MYNZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	MTVA MetaVia	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
4/16/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/21/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MTVA MetaVia	N/A	N/A	N/A	N/A	$3.44 per share	N/A
MYNZ Mainz Biomed	$893.99K	7.04	N/A	N/A	$10.82 per share	0.17
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	$1.82M	15.93	N/A	N/A	$30.46 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MTVA MetaVia	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	8/13/2025 (Estimated)
MYNZ Mainz Biomed	-$26.30M	-$65.60	N/A	N/A	N/A	N/A	N/A	N/A	7/1/2025 (Estimated)
NLSP NLS Pharmaceutics	-$12.17M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SXTC, MTVA, NLSP, and MYNZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/1/2025	N/A	MYNZ Mainz Biomed	-$2.80	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MTVA MetaVia	-$0.57	-$0.36	+$0.21	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MTVA MetaVia	N/A	2.41	2.41
MYNZ Mainz Biomed	N/A	0.24	0.19
NLSP NLS Pharmaceutics	N/A	0.15	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MTVA MetaVia	1.37%
MYNZ Mainz Biomed	N/A
NLSP NLS Pharmaceutics	N/A
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
MTVA MetaVia	1.05%
MYNZ Mainz Biomed	18.20%
NLSP NLS Pharmaceutics	16.40%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MTVA MetaVia	8	19.56 million	8.53 million	N/A
MYNZ Mainz Biomed	30	3.44 million	1.64 million	Not Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	3.90 million	Not Optionable

SXTC, MTVA, NLSP, and MYNZ Headlines

Recent News About These Companies

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.com

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.com

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 2, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.com

JAGX, BSGM and SXTC among mid-day movers

April 16, 2024 | msn.com

China SXT Pharmaceuticals Inc.

February 23, 2024 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, MTVA, NLSP, and MYNZ Company Descriptions

MetaVia NASDAQ:MTVA

$0.73 -0.02 (-2.39%)

As of 06/13/2025 03:58 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Mainz Biomed NASDAQ:MYNZ

$1.83 -0.16 (-8.04%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.77%)

As of 06/13/2025 07:56 PM Eastern

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

NLS Pharmaceutics NASDAQ:NLSP

$2.28 -0.11 (-4.60%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.28 +0.01 (+0.22%)

As of 06/13/2025 07:56 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.83 -0.21 (-10.29%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.82%)

As of 06/13/2025 07:49 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time